Previous and Current Research

Martin Bornhäuser leads the clinical transplantation program within the Medizinische Klinik und Poliklinik I which has become the second largest center for allogeneic HSCT in Germany. About 150 allogeneic and 60 autologous transplants are performed each year. One special focus is the development of allogeneic stem cell transplantation in novel indications, e.g. for the therapy of high-risk autoimmune disease (Bornhauser et al. 2010).  The GMP units located in the department of haematology have allowed developing new cellular therapies including the use of third-party MSC and regulatory T cells for the treatment of acute and chronic Graft-versus Host disease (von Bonin et al.,  2009). Efforts to improve the efficacy of adoptive immunotherapy after transplantation by the infusion of ex-vivo activated donor CD8+ T cells have been successful in patients with chronic myeloid leukaemia (Bornhauser et al., 2011).

Preclinical research has been focuses on the interaction of HSC and MSC during coculture and the relevance of endogenous BMP production and the substrate elasticity for the functional properties of MSC (Seib et al.,  2009a and 2009b).

Selected Publications

Bornhauser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Holig C, Radke J, Tuve S, Wermke M, Wehner R, Jahnisch H, Bachmann M, Rieber EP, Schetelig J, Ehninger G, Schmitz M (2011): Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T-Cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood in press

Bornhauser M, Aringer M, Thiede C (2010): Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. N. Engl. J. Med. 362, 2431-2432

Seib FP, Franke M, Jing D, Werner C, Bornhauser M (2009a): Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells. Eur J Cell Biol 88, 257-271.

Seib FP, Prewitz M, Werner C, Bornhauser M (2009b): Matrix elasticity regulates the secretory profile of human bone marrow-derived multipotent mesenchymal stromal cells (MSCs). Biochem. Biophys. Res. Commun. 389, 663-667

von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M (2009): Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43, 245-251.

For more information, please visit our stem cell lab homepage!